Johnson & Johnson (JNJ)[Tv]

Key Events

• FDA approval of TREMFYA’s label expansion for halting structural joint damage in psoriatic arthritis – This landmark decision marks the first-in-class demonstration of disease modification in psoriatic arthritis, backed by 57% reduction in radiographic progression from the APEX trial, reinforcing JNJ’s leadership in autoimmune therapeutics.
• $1 billion acquisition of Firefly Bio, Inc. to integrate degrader-antibody conjugate platform into oncology pipeline – The transformative deal positions JNJ at the forefront of targeting "undruggable" KRAS-driven solid tumors, with the transaction expected to close in 2026 and unlock next-generation oncology potential.
• Los Angeles jury verdict awarding $32 million in a talc-linked mesothelioma lawsuit – Despite prior favorable outcomes, this verdict underscores the ongoing severity of JNJ’s legal overhang, highlighting the persistent risk of catastrophic liability and eroding long-term investor confidence.
• FDA Priority Review of IMAAVY for wAIHA – This near-term catalyst validates JNJ’s precision immunology platform and signals transformative potential for a rare, life-threatening condition, offering first-in-class therapy and premium labeling upside.
• Record Q1 2026 revenue growth of 9.9% to $24.06B, driven by TREMFYA, CARVYKTI, and DARZALEX – The strong top-line performance confirms JNJ’s ability to rapidly replace lost Stelara sales with diversified innovation, reinforcing momentum in core pharma franchises.